Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.32 |
| ▸ | PAK4 | O96013 | 2/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.32 |
| ▸ | PRKACA | P17612 | 2/20 | 0.32 |
| ▸ | CLK2 | P49760 | 2/20 | 0.32 |
| ▸ | GSK3A | P49840 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.32 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.32 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | PLK4 | O00444 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31618054 | 1.00 | CHEK1 (0.40) | CHEK1DUTPRKD3MAP4K4PAK4 | |
| SCHEMBL3285768 | 0.93 | CHEK1 (0.42) | CHEK1PRKD3MAP4K4PAK4NTRK1 | |
| SCHEMBL3224749 | 0.85 | CHEK1 (0.44) | CHEK1PRKD3MAP4K4PAK4NTRK1 | |
| SCHEMBL31361298 | 0.80 | SLC6A4 (0.36) | DUT | |
| SCHEMBL13060746 | 0.77 | CHEK1 (0.41) | CHEK1PRKD3MAP4K4PRKACACLK2 | |
| SCHEMBL16765811 | 0.76 | CHEK1 (0.49) | CHEK1PRKD3MAP4K4PAK4NTRK1 | |
| SCHEMBL3372101 | 0.76 | CHEK1 (0.40) | CHEK1AURKAJAK3 | |
| SCHEMBL13060461 | 0.76 | CHEK1 (0.40) | CHEK1PRKD3MAP4K4PRKACACLK2 | |
| SCHEMBL2783376 | 0.74 | CHEK1 (0.53) | CHEK1PRKD3MAP4K4PAK4NTRK1 | |
| SCHEMBL7249503 | 0.71 | HSP90AB1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-12-09 | — | — | US | disclosed |
| US-7713941-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-05-11 | — | — | US | disclosed |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2008-08-21 | — | — | US | disclosed |
| US-7268119-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-09-11 | — | — | US | disclosed |
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | CHEK1 484/4885DUT 21/4885PRKD3 675/4885 |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | NME1, NME2, NTPCR | CHEK1 444/4885DUT 14/4885PRKD3 696/4885 |
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | CHEK1 484/4885DUT 21/4885PRKD3 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.